

# Effect of unifaceted and multifaceted interventions on antibiotic prescription control for respiratory diseases A systematic review of randomized controlled trials

Yue Chang, PhD<sup>a</sup>, Zhezhe Cui, PhD<sup>b</sup>, Xun He, MS<sup>a</sup>, Xunrong Zhou, MS<sup>c</sup>, Hanni Zhou, MS<sup>a</sup>, Xingying Fan, MS<sup>a</sup>, Wenju Wang, MS<sup>d</sup>, Guanghong Yang, MD<sup>d,\*</sup>

# Abstract

**Background:** The global health system is improperly using antibiotics, particularly in the treatment of respiratory diseases. We aimed to examine the effectiveness of implementing a unifaceted and multifaceted intervention for unreasonable antibiotic prescriptions.

**Methods:** Relevant literature published in the databases of Pubmed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure and Wanfang was searched. Data were independently filtered and extracted by 2 reviewers based on a pre-designed inclusion and exclusion criteria. The Cochrane collaborative bias risk tool was used to evaluate the quality of the included randomized controlled trials studies.

**Results:** A total of 1390 studies were obtained of which 23 studies the outcome variables were antibiotic prescription rates with the number of prescriptions and intervention details were included in the systematic review. Twenty-two of the studies involved educational interventions for doctors, including: online training using email, web pages and webinar, antibiotic guidelines for information dissemination measures by email, postal or telephone reminder, training doctors in communication skills, short-term interactive educational seminars, and short-term field training sessions. Seventeen studies of interventions for health care workers also included: regular or irregular assessment/audit of antibiotic prescriptions, prescription recommendations from experts and peers delivered at a meeting or online, publicly reporting on doctors' antibiotic usage to patients, hospital administrators, and health authorities, monitoring/feedback prescribing behavior to general practices by email or poster, and studies involving patients and their families (n = 8). Twenty-one randomized controlled trials were rated as having a low risk of bias while 2 randomized controlled trials were rated as having a low risk of bias while 2 randomized controlled trials contained negative results.

**Conclusion:** The combination of education, prescription audit, prescription recommendations from experts, public reporting, prescription feedback and patient or family member multifaceted interventions can effectively reduce antibiotic prescription rates in health care institutions. Moreover, adding multifaceted interventions to educational interventions can control antibiotic prescription rates and may be a more reasonable method.

Registrations: This systematic review was registered in PROSPERO, registration number: CRD42020192560.

**Abbreviations:** APR = antibiotic prescription rate, CI = confidence interval, GPs = general practitioners, RCT = randomized controlled trial, RD = risk difference.

Keywords: antibiotic prescriptions, randomized controlled trial, respiratory diseases, systematic evaluation

This study was due to a grant obtained from the National Natural Science Foundation of China Grant on "Research on feedback intervention mode of antibiotic prescription control in primary medical institutions based on the depth graph neural network technology" (71964009) and the Science and Technology Fund Project of Guizhou Provincial Health Commission Grant on "Application Research of Deep Learning Technology in Rational Evaluation and Intervention of Antibiotic Prescription" (gzwjkj2019-1-218).

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Supplemental Digital Content is available for this article.

<sup>a</sup> School of Medicine and Health Management, Guizhou Medical University, Guiyang, China, <sup>b</sup> Guangxi Key Laboratory of Major Infectious Disease Prevention and Control and Biosafety Emergency Response, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, China, <sup>c</sup> The Second Affiliated Hospital, Guizhou University of Chinese Medicine, Guiyang, China, <sup>d</sup> School of Public Health, Guizhou Medical University, Guiyang, China.

\*Correspondence: Guanghong Yang, School of Public Health, Guizhou Medical University, Guiyang, China (e-mail: 280446859@qq.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Chang Y, Cui Z, He X, Zhou X, Zhou H, Fan X, Wang W, Yang G. Effect of unifaceted and multifaceted interventions on antibiotic prescription control for respiratory diseases: A systematic review of randomized controlled trials. Medicine 2022;101:41(e30865).

Received: 26 May 2022 / Received in final form: 29 August 2022 / Accepted: 31 August 2022

http://dx.doi.org/10.1097/MD.000000000030865

YC, ZC, and XH contributed equally to this work.

# 1. Introduction

The discovery of antibacterial drugs is an important milestone in the history of human medical science. The emergence of antibiotics has changed the outcome of infections, thereby extending people's life expectancy.<sup>[1]</sup> However, in the past decade, 50% of the world's antibiotic prescriptions have been misused to treat coughs and colds, and many of these prescriptions have no indications for antibiotic use.<sup>[2]</sup> According to our previous research,<sup>[3]</sup> most unreasonable antibiotic prescriptions are used to treat these uncomplicated respiratory infections caused by viruses, which is common in many countries of the world.<sup>[4-9]</sup> As a result, globally, 4.95 million people died in 2019 from bacterial antimicrobial resistance caused by overuse and misuse of antibiotics. If unchecked, this figure could rise to 10 million by 2050, surpassing cancer as the leading cause of death.<sup>[10,11]</sup> Previous studies have shown that implementing unifaceted or multifaceted interventions for medical staff, patients and caregivers can effectively reduce antibiotic misuse and thus curb antibiotic resistance.<sup>[12,13]</sup> There are 2 Cochrane Systematic Reviews on interventions to improve antibiotic prescribing; one is in the ambulatory care setting<sup>[14]</sup> and the other is among hospital inpatients.<sup>[15]</sup> The ambulatory care review has not been updated since 2005 but more recent systematic reviews have been published about interventions in primary care, especially for respiratory diseases<sup>[12,13,16]</sup> and care homes.<sup>[17]</sup> They focused specifically on primary care institutions and physicians, or systematic reviews of educational interventions. There is strong evidence that educational interventions improve antibiotic prescribing but more evidence is required about the effectiveness of supplementing education with additional intervention elements and on the sustainability of interventions in a wider range of studies and study subjects. The antibiotic prescription rate (APR) is the main outcome indicator of interventions to control antibiotic prescriptions in those studies.<sup>[15,16]</sup>

To further confirm the effectiveness of various interventions on antibiotic prescription misuse and overuse in respiratory diseases, we used the Cochrane systematic review and meta-analysis methods to evaluate published results of relevant randomized controlled trials (RCTs) to provide a reference for relevant decision-makers.

# 2. Materials and Methods

### 2.1. Protocol and registration

This systematic review was conducted using the PRISMA reporting guidelines (Appendix 1, Supplemental Digital Content, http://links.lww.com/MD/H434)<sup>[18]</sup> and was registered in PROSPERO with registration number CRD42020192560. The study was approved by the Human Trial Ethics (Appendix 2, Supplemental Digital Content, http://links.lww.com/MD/H435) Committee of Guizhou Medical University (Certificate No.: 2019 (148)) in December 27, 2019.

### 2.2. Inclusion criteria

The inclusion criteria of this study were based on the full-text information available in the English and Chinese literature databases and also included the following:

- (1) The study objective focused on respiratory diseases;
- (2) RCTs of intervention and control groups with measurements collected both before and after the intervention;
- (3) Intervention targets were medical staff (general practitioners, physicians, nurses), patients and caregivers;
- (4) The interventions were clearly described.

#### 2.3. Exclusion criteria

- (1) Cross-sectional studies, cohort studies, case-control studies;
- (2) Systematic reviews, intervention protocols and letters;
- (3) Duplicate studies.

### 2.4. Selection strategy and information sources

A systematic literature search was conducted in PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure and Wanfang databases. The search period was from the time of construction of the database to February 28, 2022. We collected published studies in English or Chinese evaluating the effectiveness of antibiotic prescription interventions. Keywords and search terms used included ("Antibiotic prescription" or "Antimicrobial prescription") and ("Intervention") and ("Respiratory"). Appendix 3 (Supplemental Digital Content, http://links.lww.com/MD/ H560) contains an example of the search strategy. Data were independently filtered and extracted based on the pre-designed inclusion and exclusion criteria.

# 2.5. Study setting

Referring to Vodicka et al<sup>[19]</sup> and Roque et al,<sup>[12]</sup> study settings included: primary care; hospital care; health care center; and nursing homes.

#### 2.6. Study design

Study designs included: cluster randomized controlled trial and RCT.

#### 2.7. Primary outcomes and findings

The primary outcomes and findings of studies were adapted from Roque et al.<sup>[12,20]</sup> The primary outcome was APR. The primary findings included: (+) positive findings ( $\pm$ ), negative findings (–), both positive and negative ( $\pm$ ).

### 2.8. Summary of APR for respiratory diseases

In the RCT studies we included, we performed a more detailed analysis if the outcome variable was the APR (defined as antibiotic prescriptions/total prescriptions  $\times$  100%) and there was a detailed prescription quantity report or it could be inferred indirectly from the literature.

#### 2.9. Risk of bias assessment

The first 2 authors (YC and ZC) read the abstracts of all uncertain studies and the full-text of all studies that were still uncertain. A final agreement to include or exclude the studies was done after discussion of the discrepancies. The risk of bias in the included studies was independently assessed according to the "Cochrane systematic reviewer's manual."<sup>[21]</sup> There are 7 items in the criteria: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome bias (attrition bias), selective reporting (reporting bias) and other bias. The bias risk assessment scoring criteria for each study were: "low risk" when all items were rated "low" or one or two of them were "unclear." If one or more items were rated "high" and more than one "unclear," it was rated as "high risk." RevMan 5.3 software was used to show the results.

# 2.10. Meta-analysis

We conducted a meta-analysis of all the studies selected for the systematic review, and the study objects were the medical records of the intervention group and the control group after the intervention. The risk difference (RD) of APR of the 2 groups was combined, and the combined effect value and 95% confidence interval (95% CI) were calculated. The *T* test and chi-square test statistics were used to analyze the heterogeneity between the results (a = 0.05), a fixed effect model (P > .05) or a random effect model ( $P \le .05$ ) will be determined. If  $I^2 < 50\%$ , a fixed effect model was used; if  $I^2 \ge 50\%$ , a random effect model was used. If there was still significant heterogeneity in the research results, a subgroup analysis or a descriptive analysis is required. RevMan 5.3 software was employed for meta-analysis.

# 3. Results

The search and selection process are shown in Figure 1. A total of 1390 studies were obtained, of which 384 were excluded after reading the title and abstract. The remaining 1006 studies were further screened by reading the full-text, of which 916 were excluded: 190 because they were treatment or drug intervention trials, 25 because they were antibiotic cost-benefit analysis studies, 170 because they were systematic reviews or cohort studies such as non-RCTs, 390 because they were observational studies (cross-sectional studies, and case-control studies), 125 because they were duplicate studies, and 15 studies because the full-text could not be accessed. Finally, of the 91 eligible studies, a total of 23 studies were included in the systematic review and meta-analysis after excluding 68 studies that did not have APR as the outcome variable.




Figure 1. PRISMA screening flow chart. APR = antibiotic prescription, RCT = randomized controlled trial.

#### 3.1. Basic characteristics of the included studies

As shown in Table 1, of the 23 studies included, 17[23-32,34,37-<sup>40,42,43]</sup> were cluster randomized controlled trial, 6<sup>[22,33,35,36,41,44]</sup> were RCT. Eighteen<sup>[22,23,26-32,34,36-42,44]</sup> studies were conducted in primary care settings (including general practice clinics, family practices and township hospitals), 3<sup>[24,33,35]</sup> hospital-based studies and 1<sup>[25]</sup> in health care center, and 1<sup>[43]</sup> in nursing homes. General practitioners (GPs) were participants of  $10^{[22,23,26-28,32,35,36,39,40]}$  intervention studies. Therefore, the authors suggested that future research should be aimed at GPs. Participants in the other 10 studies included: physicians (n = 4),<sup>[25,38,43,44]</sup> and (n = 2),<sup>[24,41]</sup>; family physicians (n = 2),<sup>[24,41]</sup>; health providers (n = 5),<sup>[29,30,33,37,42]</sup> which were faculties at a clinical practices center; and all kinds of patients (n = 7).<sup>[22,26,32,36-39]</sup> Fourteen<sup>[22,25,27-30,32-35,37,40-42]</sup> studies were for respiratory diseases in all patients, and the remaining 10

# Table 1

studies were of children (n = 3), <sup>[38,39,44]</sup> adults (n = 3), <sup>[24,26,36]</sup> elderly (n = 1),<sup>[43]</sup> and patients aged 18 to 65 (n = 2).<sup>[23,31]</sup> Eighteen<sup>[22–27,29,30,32–34,36,38,39,41–44]</sup> studies had intervention periods of less than 1 year or unclear.

In Table 2, a total of 23 RCTs were included in the review, including 1<sup>[33]</sup> published in Chinese and 22<sup>[22-32,34-44]</sup> in English. The studies involved 396,959/1,911,248 prescriptions (antibiotic prescriptions/the total prescriptions) from Germany,<sup>[26]</sup>, Singapore,<sup>[36]</sup> Switzerland,<sup>[28]</sup> France,<sup>[35]</sup> and Belgium<sup>[23]</sup> (187,156/978,472 in the intervention group and 209,803/932,776 in the control group). Four<sup>[27,30,36,41]</sup> of the study's control groups received a partial intervention. Seventeen studies<sup>[22,24-27,29,31-35,37-41,43]</sup> had positive results (+, The primary results in the intervention groups were superior to those in the control groups). Two study<sup>[23,42]</sup> had negative results

Basic characteristi	cs of the 23 stu	udies.				
Study	Design*	Settings <sup>†</sup>	Diseases <sup>‡</sup>	Participants <sup>§</sup>	Patients	Duration
Ineke W, et al Netherland 2004 <sup>[22]</sup>	RCT	PC	RTIs	GPs and pharmacists and patients	All	9 mo
Coenen S, et al Belgium 2004 <sup>[23]</sup>	cRCT	PC	Acute cough	GPs	Adult (18–65)	2 mo
Metlay JP, et al USA 2007 <sup>[24]</sup>	cRCT	HP	ARTIs	Clinicians and patients	Adult (>18)	4 mo
Monette J, et al Canada 2007 <sup>[25]</sup>	cRCT	HCc	RTIs and others	Physicians	All	3 mo
Altiner A, et al Germany 2007 <sup>[26]</sup>	cRCT	PC	Acute cough	GPs and patients	Adult (≥16)	Unclear
Gjelstad S, et al Norway 2013 <sup>[27]</sup>	cRCT	PC	ARTIs	GPs	All	6 mo
Hürlimann D, et al Switzerland 2014 <sup>[28]</sup>	cRCT	PC	RTIs	GPs	All	2 yr
Yang L, et al China 2014 <sup>[29]</sup>	cRCT	PC	URTIs	HPs	All	Unclear
Chen Y, et al China 2014 <sup>[30]</sup>	cRCT	PC	URTIs	HPs	All	40 d
Gulliford MC, et al England 2014 <sup>[31]</sup>	cRCT	PC	RTIs	FPs	Adult (18–59)	1 yr
Velden AW, et al Netherlands 2015 <sup>[32]</sup>	cRCT	PC	RTIs	GPs and patients	All	1 yr
Qiu JG, et al China 2016 <sup>[33]</sup>	RCT	HP	RTIs	HPs	All	Unclear
Vervloet M, et al Netherland 2016 <sup>[34]</sup>	cRCT	PC	RTIs	FPs	All	6 mo
Ferrat E, et al France 2016 <sup>[35]</sup>	RCT	HP	RTIs	GPs	All	4.5 yr
Lee MHM, et al Singapore 2017 <sup>[36]</sup>	RCT	PC	URTIs	Patients	Adult (≥21)	9 d
Tang YQ, et al China 2017 <sup>[37]</sup>	cRCT	PC	URTIs	HPs and patients	All	1 yr
Wei XL, et al China 2017 <sup>[38]</sup>	cRCT	PC	URTIs	Physicians and caregivers	Children (2–14)	6 mo
Dekker ARJ, et al England 2018 <sup>[39]</sup>	cRCT	PC	RTIs	GPs and caregivers	Children	Unclear
Gulliford MC, et al England 2019 <sup>[40]</sup>	cRCT	PC	RTIs	GPs	All	1 yr
Lily DY, et al USA2020 <sup>[41]</sup>	RCT	PC	ARTIs	Clinicians	All	11 mo
Mann D, et al USA2020 <sup>[42]</sup>	cRCT	PC	ARTIs	HPs	All	7 mo
Tjarda MB, et al Netherlands2021 <sup>[43]</sup>	cRCT	NH	LRTIs	Physicians	Elderly	7 mo
Zahlanie Y, et al USA2021 <sup>[44]</sup>	RCT	PC	RTIs	Physicians	Children	6 mo

\*Design: cRCT = cluster randomized controlled trial, RCT = randomized controlled trial.

+Setting: HCc = Health care center, HP = Hospital, NH = nursing homes, PC = primary care.

‡Diseases: ARTIs = acute respiratory tract infections, LRTIs = lower respiratory tract infections, RTIs = respiratory tract infections, URTIs = upper respiratory tract infections. §Participants: FPs = family physicians, GPs = general practitioners, HPs = health providers.

# Table 2

#### Basic characteristics of the 23 APR studies.

www.md-journal.com

				d in the study (antibiotic otal prescriptions)		
Author Year		Country	Intervention group	Control group	Control group intervention-	Primary findings
Ineke W, et al <sup>[22]</sup>	2004	Netherlands	60/261	39/105	_	(+)
Coenen S, et al <sup>[23]</sup>	2004	Belgium	80/292	115/401	Partial intervention	(-)
Metlay JP, et al <sup>[24]</sup>	2007	USĂ	483/1510	637/1342	-	(+)
Monette J,et al <sup>[25]</sup>	2007	Canada	309/1326	154/431	-	(+)
Altiner A, et al <sup>[26]</sup>	2007	Germany	289/787	596/920	-	(+)
Gjelstad S, et al <sup>[27]</sup>	2013	Norway	21,246/66,757	23,307/66,501	Partial intervention	(+)
Hürlimann D, et al <sup>[28]</sup>	2014	Switzerland	15,952/41,580	13,654/45,737	-	(±)
Yang L, et al <sup>[29]</sup>	2014	China	11,184/12,774	9824/10,369	-	(+)
Gulliford MC, et al <sup>[31]</sup>	2014	England	34,313/317,717	32,569/285692	-	(+)
Chen Y,et al <sup>[30]</sup>	2014	China	568/831	299/446	Partial intervention	(±)
Velden AW, et al <sup>[32]</sup>	2015	Netherlands	895/3461	974/3421	-	(+)
Qiu JG, et al <sup>[33]</sup>	2016	China	107/150	143/150	-	(+)
Vervloet M, et al <sup>[34]</sup>	2016	Netherlands	9589/23,500	14,603/23,500	-	(+)
Ferrat E, et al <sup>[35]</sup>	2016	France	9916/70,830	17,708/10,6036	-	(+)
Lee MHM, et al <sup>[36]</sup>	2017	Singapore	94/457	81/457	Partial intervention	(±)
Tang YQ, et al <sup>[37]</sup>	2017	China	14,649/17,021	13,219/14,937	-	(+)
Wei XL, et al <sup>[38]</sup>	2017	China	943/2351	1782/2552	-	(+)
Dekker ARJ, et al <sup>[39]</sup>	2018	England	102/475	176/531	-	(+)
Gulliford MC, et al <sup>[40]</sup>	2019	England	37,601/348,158	40,099/27,8467	-	(+)
Lily DY, et al <sup>[41]</sup>	2020	USA	13,604/25,513	18,352/31,429	Partial intervention	(+)
Mann D, et al <sup>[42]</sup>	2020	USA	14,723/42,126	20,765/58,447	-	()
Tjarda MB, et al <sup>[43]</sup>	2021	Netherlands	89/162	65/79		(+)
Zahlanie Y, et al <sup>[44]</sup>	2021	USA	360/433	642/826	-	(±)

Primary findings: (+) = positive findings, (-) = negative findings, (±) = positive and negative findings. The guidelines, coupled with sustained personal feedback, did not reduce APR but increased the use of recommended antibiotic.

We originally planned to do a meta-analysis of 23 RCTs the study objects were the medical records of the intervention group and the control group after the intervention. The RD of APR of the two groups was combined, and the combined effect value and 95% confidence interval were calculated. However, even when the random impact model was used, the heterogeneity was still significant ( $l^2 = 99\%$ ), so a sensitivity analysis and subgroup analysis were conducted. After the sensitivity analysis, we attempted to conduct a subgroup analysis on factors such as age group of patients, cluster or non-cluster, random or nonrandom, study area, intervention methods, duration of intervention and randomness, to explore the causes of heterogeneity. RD was used to control the confounders. Nevertheless, the high heterogeneity of all subgroups led us to perform a descriptive review of the literature.

APR = antibiotic prescription rate, RCT = randomized controlled trial, RD = risk difference.

(-, The primary results in the control groups were superior to those in the intervention groups). Four study<sup>[28,30,36,44]</sup> had negative and positive results ( $\pm$ , Some of the results were better in the intervention group than in the control group).

#### 3.2. Interventions of included APR studies

Table 3 shows the categories of interventions included in the APR studies. Twenty two<sup>[22–35,37-44]</sup> of the 23 studies involved educational interventions, including: (1) online training using email, web pages and webinars containing guidelines and communication skills,<sup>[23,39-42,44]</sup> (2) antibiotic guidelines for information dissemination measures by email, postal or telephone reminder,<sup>[23–25,28,33,35,37,38,40,42,43]</sup> (3) training doctors in communication skills,<sup>[22,25,26,34,38,39]</sup> (4) short-term interactive educational seminars,<sup>[22,24,27,32,33,35,38,40,42,44]</sup> and (5) short-term field training,<sup>[22,24,27,32,33,35,38,40,42,44]</sup> and (5) short-term field training,<sup>[22,24,27,32,33,35,38,43,44]</sup> the latter 2 types of training methods were generally face-to-face (on-site) interventions and the duration was usually hours or days of diagnostic and drug guidance, rapid testing method, of which 8 studies comprehensively used more than 2 educational interventions, and all of these studies had positive results.

Twenty-three studies of interventions for health care workers also included: (6) regular or irregular assessment/audit of antibiotic prescriptions<sup>[22,25,27,32–34,38,40]</sup> and (7) prescription recommendations from experts and peers delivered at a meeting or online.<sup>[23–26,30–32,34]</sup> Vervloet et al<sup>[34]</sup> implemented a prescription recommendation in an Electronic Prescribing System. When a family physician tried to prescribe an antibiotic to a patient with respiratory tract infections, the Electronic Prescribing System immediately prompted an alert with the message "no prescription," and if the doctor still wanted a prescription, a pop-up window containing the message "delayed prescription" would appear. After acknowledging these 2 electronic alerts, the doctor could write a prescription. (8) Two studies<sup>[29,37]</sup> reported publicly on doctors' antibiotic usage to patients, hospital administrators, and health authorities. The report contained APR, injection for APR, cost, and peer ranking. (9) Eleven studies reported monitoring/feedback prescribing behavior to GPs by email or poster (the prescribing behavior of individual physicians for 6 months or 1 year).<sup>[22,24,25,27-29,32,34,37,40,41]</sup>

Among the studies of interventions, 8<sup>[22,24,26,29,32,36,38,39]</sup> involved patients and their families, including the distribution of leaflets and brochures on the rational use of antibiotics, the installation of multimedia education systems or poster/video in waiting rooms, and the use of flyers and posters. One<sup>[36]</sup> of the studies involved only patients and family members.

# 3.3. Risk of bias

As shown in Figure 2, 21 studies<sup>[22–24,26–32,34–44]</sup> were rated as having a low risk of bias while 2<sup>[25,33]</sup> were rated as having a high risk of bias. Figure 2 shows the risk of bias assessment for each criterion. Among the 23 studies, 1<sup>[33]</sup> in the "Random Sequence Generation" section were determined to have a high risk of bias as the one did not describe the sampling method. Although the study stated itself as using a randomized approach, the process described by it is more likely to be grouped according to the availability of interventions. One study<sup>[25]</sup> was identified as having a high risk of bias in the "Blinding of outcome assessment" section due to a lack of random sampling and unblinded

		Eq	Educational intervention	tion								
				On-site intervention*	ntion*							
Author (yr)	(1) Online training	(2) Distribution of educational materials	(3) Communication skill	(4) Short-term interactive education seminar	(5) Short- term field training	(6) Prescription audit	(7) Prescription recommendations from experts <sup>†</sup>	(8) Public reporting	(9) Prescription feedback	Brochure	Flyers and posters	Waiting room education
Ineke W (2004) <sup>[22]</sup>			~	^	~				~	~	>	
Coenen S (2004) <sup>[23]</sup>	>	~					~					
Metlay JP (2007) <sup>[24]</sup>		~		$\overline{}$	>		~		$\mathbf{i}$	>	>	$\rightarrow$
Monette J (2007) <sup>[25]</sup>		~	$\overline{}$			$\mathbf{i}$	~		~			
Altiner A (2007) <sup>[26]</sup>			>				$\overline{}$				>	
Gjelstad S (2013) <sup>[27]</sup>				~	$\overline{}$	>			7			
Hürlimann D (2014) <sup>[28]</sup>		$\overline{}$							$\overline{}$			
Yang L (2014) <sup>[29]</sup>							-	>	~		>	
Gnen Y (2014) <sup>bou</sup> Guiliford MC (2014) <sup>bou</sup>							> -					
Velden AW (2015) <sup>[32]</sup>				/	1	/	~ ~		1	1		1
Qiu JG (2016) <sup>[33]</sup>		7		~ ~	~~	~ ~	*		•	•		-
Vervloet M (2016) <sup>[34]</sup>			~			~	~		~			
Ferrat E (2016) <sup>[35]</sup>		~		~	>							
Lee MHM (2017) <sup>[36]</sup>										>		>
Tang YQ (2017) <sup>[37]</sup>		>						>	~			
Wei XL (2017) <sup>[38]</sup>		>	>	$\overline{}$	>	>					>	>
Dekker ARJ (2018) <sup>[39]</sup>	>		~							>		
Gulliford MC (2019) <sup>[40]</sup>	>	>		$\overline{}$		>			>			
Lily DY (2020) <sup>[41]</sup>	>								~			
Mann D (2020) <sup>[42]</sup>	>	>		$\overline{}$								
Tjarda MB (2021) <sup>[43]</sup>		>			>							
Zahlanie Y (2021) <sup>[44]</sup>	>			~	~							

Table 3

Medicine




Figure 2. Risk of bias summary.

nature. Nineteen studies<sup>[23-28,31-37,39-44]</sup> showed an unclear risk of bias in 6 domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome bias, and other bias. Only four<sup>[22,29,30,38]</sup> of the studies were low risk of bias in all domains. In the domain of "Allocation concealment," 12 studies<sup>[24,26-28,31-34,39,40,42,43]</sup> were judged as having unclear risks of bias. The main reason is that no information was provided about the process of generating random sequences in these studies. This can lead to selection bias. In the domain of "Blinding of participants and personnel," 11 studies<sup>[24,26,27,31-33,35,37,39,42,43]</sup> were judged as having unclear risks of bias. The reason is that there was not enough information to determine "low risk" or "high risk." There may be a risk of performance bias. In the domain of "blinding of outcome assessment," 7 studies<sup>[23,27,28,31,32,34,43]</sup> were judged to have "unclear risk of bias" due to lack of information. Detection bias is likely to arise. In the domain of "incomplete outcome bias," 1 study<sup>[24]</sup> was judged to have an unclear risk of bias because it did not provide a random number of people and lacked data. This has the potential to create attrition bias. Finally, in the domain of "Other bias," 11 studies<sup>[23,25,28,32-34,36,37,41,43,44]</sup> were judged to have unclear risk of bias because these authors did not provide enough information to determine whether there was a significant risk of bias.

#### 3.4. Evaluation of publication bias

According to the included studies, the inverted funnel chart was produced, which has poor symmetry and may have publication bias. See Figure 3 for details.

# 3.5. Meta-analysis

Figures 4 and 5 shows a meta-analysis of 23 studies of antibiotic prescription samples. The heterogeneity test showed that the results of antibiotic prescription interventions were significantly different ( $\chi^2 = 4569.23$ , P < .00001,  $I^2 = 99\%$ ), so a random-effects model was chosen. The results of the combined analysis showed that the RD was significant and favored the experimental group (RD = -0.07.14, 95% CI = -0.0896, -0.0533, P < .00001). The rate of antibiotic prescriptions in these studies significantly decreased after the implementation of feedback intervention. However, due to the high heterogeneity ( $I^2 = 99\%$ ), a sensitivity analysis and subgroup analysis were not applicable. The forest plot without summary pooled effect were developed to provide visual information for various magnitudes of effect observed. The APR in these studies decreased after the implementation of feedback intervention, except 4 studies (DH, YC, MHML, and YZ). The results of 4 (SC, YC, MHML, and DM) studies fell on the invalid line, indicating that there was no difference between intervention groups and control groups.

# 4. Discussion

A total of 1390 studies were obtained of which 23 studies the outcome variables were APR with the number of prescriptions and intervention details were included in the study. In the 23




Figure 3. Inverted funnel plot of the effects of interventions on doctors' antibiotic prescription.

	Experimental Control Risk Difference		Risk Difference		Risk Difference			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Coenen S 2004	80	292	115	401	3.0%	-0.0128 [-0.0805, 0.0548]	2004	
Ineke W 2004	60	261	39	105	1.9%	-0.1415 [-0.2471, -0.0360]	2004	
Altiner A 2007	289	787	596	920	3.9%	-0.2806 [-0.3263, -0.2349]	2007	
Metlay JP 2007	483	1510	637	1342	4.3%	-0.1548 [-0.1904, -0.1192]	2007	- <b>-</b>
Monette J 2007	309	1326	154	431	3.7%	-0.1243 [-0.1749, -0.0736]	2007	_ <b>_</b>
Gjelstad S 2013	21246	66757	23307	66501	5.2%	-0.0322 [-0.0373, -0.0272]	2013	•
Chen Y 2014	568	831	299	446	3.6%	0.0131 [-0.0408, 0.0670]	2014	<b>-</b>
Gulliford MC 2014	34313	317717	32569	285692	5.2%	-0.0060 [-0.0076, -0.0044]	2014	•
Hürlimann D 2014	15952	41580	13654	45737	5.2%	0.0851 [0.0788, 0.0914]	2014	•
Yang L 2014	11184	12774	9824	10369	5.1%	-0.0719 [-0.0791, -0.0648]	2014	•
Velden AW 2015	895	3461	974	3421	4.8%	-0.0261 [-0.0471, -0.0051]	2015	
Ferrat E 2016	9916	70830	17708	106036	5.2%	-0.0270 [-0.0304, -0.0236]	2016	•
Qiu JG 2016	107	150	143	150	2.6%	-0.2400 [-0.3199, -0.1601]	2016	
Vervloet M 2016	9589	23500	14603	23500	5.1%	-0.2134 [-0.2222, -0.2045]	2016	•
Lee MHM 2017	94	457	81	457	3.7%	0.0284 [-0.0225, 0.0794]	2017	
Tang YQ 2017	14649	17021	13219	14937	5.1%	-0.0243 [-0.0316, -0.0170]	2017	•
Wei XL 2017	943	2351	1782	2552	4.7%	-0.2972 [-0.3238, -0.2705]	2017	
Dekker ARJ 2018	102	475	176	531	3.5%	-0.1167 [-0.1712, -0.0622]	2018	
Gulliford MC 2019	37601	348158	40099	278467	5.2%	-0.0360 [-0.0377, -0.0343]	2019	•
Lily DY 2020	13604	25513	18352	31429	5.1%	-0.0507 [-0.0589, -0.0425]	2020	+
Mann D 2020	14723	42126	20765	58447	5.2%	-0.0058 [-0.0118, 0.0002]	2020	•
McIsaac W 2021	218	634	126	328	3.1%	-0.0403 [-0.1046, 0.0240]	2021	
Tjarda MB 2021	89	162	65	79	1.7%	-0.2734 [-0.3872, -0.1596]	2021	
Zahlanie Y 2021	360	433	642	862	3.9%	0.0866 [0.0409, 0.1324]	2021	
Total (95% CI)		979106		933140	100.0%	-0.0714 [-0.0896, -0.0533]		•
Total events	187374		209929					
Heterogeneity: Tau² =	0.00; Ch	² = 4569.	23, df = 2	3 (P < 0.0	0001); l² =	99%		-0.2 -0.1 0 0.1 0.2
Test for overall effect:	Z = 7.71 (	(P < 0.000	001)					Favours [experimental] Favours [control]

Figure 4. The forest plot of antibiotic prescription (1). Cl = confidence interval.

	Experir	nental	Con	trol	Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
neke W 2004	60	261	39	105	-0.1415 [-0.2471, -0.0360]	2004	— <b>+</b> —
Coenen S 2004	80	292	115	401	-0.0128 [-0.0805, 0.0548]	2004	
Aonette J 2007	309	1326	154	431	-0.1243 [-0.1749, -0.0736]	2007	-+
Altiner A 2007	289	787	596	920	-0.2806 [-0.3263, -0.2349]	2007	- <b>+</b> -
/letlay JP 2007	483	1510	637	1342	-0.1548 [-0.1904, -0.1192]	2007	+-
∋jelstad S 2013	21246	66757	23307	66501	-0.0322 [-0.0373, -0.0272]	2013	+
Hürlimann D 2014	15952	41580	13654	45737	0.0851 [0.0788, 0.0914]	2014	+
′ang L 2014	11184	12774	9824	10369	-0.0719 [-0.0791, -0.0648]	2014	+
Chen Y 2014	568	831	299	446	0.0131 [-0.0408, 0.0670]	2014	_ <del></del>
Gulliford MC 2014	37601	348158	40099	278467	-0.0360 [-0.0377, -0.0343]	2014	E E
/elden AW 2015	895	3461	974	3421	-0.0261 [-0.0471, -0.0051]	2015	+
Qiu JG 2016	107	150	143	150	-0.2400 [-0.3199, -0.1601]	2016	— <b>+</b> —
/ervloet M 2016	9589	23500	14603	23500	-0.2134 [-0.2222, -0.2045]	2016	+
errat E 2016	9916	70830	17708	106036	-0.0270 [-0.0304, -0.0236]	2016	+
.ee MHM 2017	94	457	81	457	0.0284 [-0.0225, 0.0794]	2017	-+
Tang YQ 2017	14649	17021	13219	14937	-0.0243 [-0.0316, -0.0170]	2017	+
Vei XL 2017	943	2351	1782	2552	-0.2972 [-0.3238, -0.2705]	2017	+
Dekker ARJ 2018	102	475	176	531	-0.1167 [-0.1712, -0.0622]	2018	-+
Gulliford MC 2019	34313	317717	32569	285692	-0.0060 [-0.0076, -0.0044]	2019	l l
ily DY 2020.	13604	25513	18352	31429	-0.0507 [-0.0589, -0.0425]	2020	+
/ann D 2020	14723	42126	20765	58447	-0.0058 [-0.0118, 0.0002]	2020	+
ijarda MB 2021	89	162	65	79	-0.2734 [-0.3872, -0.1596]	2021	— <b>i</b> —
Zahlanie Y 2021	360	433	642	826	0.0542 (0.0089, 0.0994)	2021	- <b>+</b>

Favours [experimental] Favours [control]

Figure 5. The forest plot of antibiotic prescription (2). Cl = confidence interval.

studies that were eventually included, GPs and physicians were the main subjects of the intervention. Fourteen studies (58%) did not have a specific population with the diseases and 13 studies (57%) had intervention periods of less than 1 year. Patient-only, long feedback intervals and non-blind nature of the intervention may have led to negative results and a high risk of bias. Of these studies, 17 (74%) had positive results and 6 (26%) contained negative results.

A further analysis of 23 studies found that all but 2 (YC and MCG) were multifaceted interventions. Educational methods were the most common interventions. Among them, the distribution of antibiotic guidelines to doctors, short training sessions

of one to several days and training in doctors' communication skills were the most common educational interventions, and they were often used in combination. In addition, interventions for health care workers included monitoring and feedback of doctors' prescribing performance to them, auditing or evaluating the rationality of prescriptions, and prescribing recommendations from experts or via an electronic prescribing system. On the basis of the above interventions, some were added to the intervention of patients or caregivers. However, it is important to note that patients cannot be given an intervention alone, or the intervention may face ineffective results.

These 23 RCTs studies investigated a wide range of interventions targeted at both clinicians and patients (education, guidelines, prescriber feedback, patient pamphlets, etc.). This makes it very difficult to meta-analysis and to interpret the results as its unclear exactly which intervention targeted at which groups and in what setting is having the impact on prescribing. It also explains why there are such high rates of heterogeneity.

We identified the final 23 RCTs using a risk of bias tool.<sup>[21]</sup> Most (21) of the studies were low risk, but 19 of them had an "unclear risk of bias" due to insufficient information. Therefore, we hope that future studies will follow standard RCT procedures (e.g., SPIRIT 2013 Checklist)<sup>[45]</sup> to conduct trials and write manuscripts.

In summary, multifaceted feedback interventions were used in most of the included studies. Therefore, the education and training of doctors in prescribing antibiotics should be strengthened, organized medical staff should delve deep into the rules and regulations of antibiotics, and make full use of pharmacology, pharmacokinetics, pharmacodynamics, and other relevant knowledge to issue prescriptions.[46,47] On this basis, various feedback interventions can be added, such as communication between experts and peers, prescription audits, and ranking of doctors in the same department. In addition, interventions can improve the awareness of patients and their families toward antibiotics, such as providing them with brochures and leaflets, displaying posters in the waiting rooms, installing a multimedia education system in waiting areas, and encouraging patients to communicate more with their physicians about the use of antibiotics. Dekker et al<sup>[39]</sup> and Metlay et al<sup>[24]</sup> adopted certain intervention measures for patients and their families based on educational intervention measures for medical staff. Altiner et al<sup>[26]</sup> studied patients and their families based on using feedback intervention for medical staff, and the degree of reduction of antibiotic utilization was significantly higher than in other studies. Therefore, according to education and training interventions, feedback interventions were used to influence the prescribing behavior of doctors and improve the cognition of patients and their families about antibiotics. This multifaceted behavioral feedback intervention might be a more rational approach to antibiotic prescription control. In terms of policymaking, health administration departments should introduce regulations and relevant policies on the administration of antibiotics to strictly control the use of antibiotics. These departments can take strong administrative interventions against the unreasonable use of antibiotics, for example, patients or consumers could only obtain antibiotics from the pharmacies based on prescriptions, and doctors can prescribe antibiotics in a hierarchical manner.

Of the 24 studies, 6 contained negative results. Four<sup>[28,30,36,44]</sup> of them were negative and positive  $(\pm)$ : Hürlimann et al<sup>[28]</sup> advocated use of an intervention that included providing guidelines for the treatment of the diseases and providing sustained, regular feedback (twice a year) on individual physicians' antibiotic prescribing behavior over a 2-year period, which did not reduce the APR, but increased the use of recommended antibiotics. Routine guidelines and long personal feedback intervals (twice yearly) may be the reason why the intervention was not so effective. Zahlanie et al<sup>[44]</sup> developed

an Pediatric educational intervention. After the intervention, antibiotic prescribing rates were higher in the intervention group (83.1% vs 77.7%; P = .024), the treatment course was shorter than that of the control group. The author believed that the problem of small sample size and multifaceted intervention methods need to be improved. Chen et al<sup>[30]</sup> conducted a 2-month intervention in which educational messages were sent to the intervention group 3 times a week. Antibiotic prescriptions did not change, and prescriptions for other drugs declined. The study said that text messages was more convenient than looking at literature for health workers, but more research is needed to confirm the effectiveness. Lee et al<sup>[36]</sup> gave patients in the intervention group 9 days of intervention in the form of pamphlets and oral education. The study did not reduce antibiotic prescribing, except among Indian patients. This suggests that intervention in patients alone has no significant effect on reducing antibiotic prescriptions. Two<sup>[23,42]</sup> of them were negative (-): Coenen's et al<sup>[23]</sup> interventions in 2002 included a clinical practice guideline for acute cough, an educational outreach visit and a postal reminder. They concluded that the intervention was effective by comparing OR values before and after the intervention [OR<sub>adi</sub> (95% CI) 5<sub>0</sub> (0.36–0.87)]. However, RD or relative risk more interpretable for clinical trials or prospective studies. When RD values of this study were compared, there was no difference between the intervention group and the control group (see Fig. 4 forest plot). Mann et al<sup>[42]</sup> implemented a clinical decision support tool to guide evidence-based evaluation and treatment of streptococcal pharyngitis and pneumonia. According to the authors, the negative results may be due to the very low adoption and utilization rates of the tool at all clinical sites.

Our study has certain limitations. First, like most systematic reviews, there is a possibility of publication bias as the majority of the studies (17/23) reported positive results. Furthermore, some studies were not included due to incomplete data and non-randomization. This limitation may have reduced the objectivity of the results to a certain extent. Second, there were different degrees of quality differences in the design of the included studies, which may have affected our results. Third, these studies were conducted in different countries. The policies and management systems of antibiotic use differ by country, thus there was a risk of information bias. Fourthly, we only focused on the APR, but did not pay attention to the rational evaluation of antibiotics.

This systematic review found that combination of education, prescription audit, prescription recommendations from experts, public reporting, prescription feedback and patient or family member interventions and other multifaceted feedback interventions can effectively reduce the rate of antibiotic prescriptions and promote the rational use of antibiotics. However, due to the above limitations, we can only conclude that adding multifaceted feedback interventions to education interventions may be a more reasonable control method. In the future, more studies need to be included to obtain more accurate information.

# Acknowledgments

We thank all of the participating institutions for providing information and assistance during the study. The authors also thank all members of the investigational team who collected the data. English grammar was revised from Edward McNeil, Prince of Songkla University, Songkhla, Thailand.

## Author contributions

All authors made substantial contributions to the development of the trial, and read and approved the final manuscript. YC, XH, and GY designed the trial. YC and HZ drafted the manuscript, and YC and ZC completed data extraction, statistical analysis, and data interpretation. GY and XZ participated in the concept, data interpretation, and manuscript revision. YC, XF, and WW are responsible for data integrity and accuracy of data analysis.

- Conceptualization: Yue Chang, Zhezhe Cui, Xun He.
- Data curation: Yue Chang, Hanni Zhou, Xingying Fan.
- Formal analysis: Zhezhe Cui, Xun He.
- Methodology: Yue Chang, Zhezhe Cui, Xingying Fan.
- Software: Xingying Fan.

Supervision: Zhezhe Cui, Guanghong Yang.

- Validation: Yue Chang, Xun He, Xunrong Zhou, Wenju Wang, Guanghong Yang.
- Visualization: Xunrong Zhou, Hanni Zhou, Wenju Wang.
- Writing original draft: Yue Chang, Wenju Wang.
- Writing review & editing: Guanghong Yang.

#### References

- World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2017-2018. Available at: https://apps.who.int/iris/handle/10665/279656 (access date December 1, 2021).
- [2] World Health Organization. Antimicrobial resistance: global report on surveillance. Available at: https://apps.who.int/iris/handle/10665/112642 (access date December 1, 2021).
- [3] Chang Y, Chusri S, Sangthong R, et al. Clinical pattern of antibiotic overuse and misuse in primary healthcare hospitals in the southwest of China. PLoS One. 2019;14:e0214779.
- [4] Bianco A, Papadopoli R, Mascaro V, Pileggi C, Pavia M. Antibiotic prescriptions to adults with acute respiratory tract infections by Italian general practitioners. Infect Drug Resist. 2018;11:2199–205.
- [5] Durkin MJ, Jafarzadeh SR, Hsueh K, et al. Outpatient antibiotic prescription trends in the United States: a national cohort study. Infect Control Hosp Epidemiol. 2018;39:584–9.
- [6] Sharma P, Finley R, Weese S, Glass-Kaastra S, McIsaac W. Antibiotic prescriptions for outpatient acute rhinosinusitis in Canada, 2007-2013. PLoS One. 2017;12:e0181957.
- [7] Butt AA, Navasero CS, Thomas B, et al. Antibiotic prescription patterns for upper respiratory tract infections in the outpatient Qatari population in the private sector. Int J Infect Dis. 2017;55:20–3.
- [8] Sun Q, Dyar OJ, Zhao L, et al. Overuse of antibiotics for the common cold – attitudes and behaviors among doctors in rural areas of Shandong Province, China. BMC Pharmacol Toxicol. 2015;16:6.
- [9] Lindberg BH, Gjelstad S, Foshaug M, Høye S. Antibiotic prescribing for acute respiratory tract infections in Norwegian primary care outof-hours service. Scand J Prim Health Care. 2017;35:178–85.
- [10] World Health Organization. Antibiotic prescribing and resistance: views from low- and middle-income prescribing and dispensing professionals. 2017.
- [11] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.
- [12] Roque F, Herdeiro MT, Soares S, Teixeira Rodrigues A, Breitenfeld L, Figueiras A. Educational interventions to improve prescription and dispensing of antibiotics: a systematic review. BMC Public Health. 2014;14:1276.
- [13] Köchling A, Löffler C, Reinsch S, et al. Reduction of antibiotic prescriptions for acute respiratory tract infections in primary care: a systematic review. Implement Sci. 2018;13:47.
- [14] Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2005;2005:CD003539.
- [15] Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543.
- [16] Van der Velden AW, Pijpers EJ, Kuyvenhoven MM, Tonkin-Crine SKG, Little P, Verheij TJM. Effectiveness of physician-targeted interventions to improve antibiotic use for respiratory tract infections. Br J Gen Pract. 2012;62:e801–7.
- [17] Nguyen HQ, Tunney MM, Hughes CM. Interventions to improve antimicrobial stewardship for older people in care homes: a systematic review. Drugs Aging. 2019;36:355–69.
- [18] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Brit Med J. 2009;339:b2535.

- [19] Vodicka TA, Thompson M, Lucas P, et al. Reducing antibiotic prescribing for children with respiratory tract infections in primary care: a systematic review. Br J Gen Pract. 2013;63:e445–54.
- [20] Steinman MA, Ranji SR, Shojania KG, Gonzales R. Improving antibiotic selection: a systematic review and quantitative analysis of quality improvement strategies. Med Care. 2006;44:617–28.
- [21] Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available at: www.training.cochrane.org/ handbook (access date March 1, 2022).
- [22] Welschen I, Kuyvenhoven MM, Hoes AW, et al. Effectiveness of a multifaceted intervention to reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised controlled trial. BMJ. 2004;329:431431.
- [23] Coenen S, Van Royen P, Michiels B, Denekens J. Optimizing antibiotic prescribing for acute cough in general practice: a cluster-randomized controlled trial. J Antimicrob Chemother. 2004;54:661–72.
- [24] Metlay JP, Camargo CA Jr, MacKenzie T, et al. Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments. Ann Emerg Med. 2007;50:221–30.
- [25] Monette J, Miller MA, Monette M, et al. Effect of an educational intervention on optimizing antibiotic prescribing in long-term care facilities. J Am Geriatr Soc. 2007;55:1231–5.
- [26] Altiner A, Brockmann S, Sielk M, Wilm S, Wegscheider K, Abholz H-H. Reducing antibiotic prescriptions for acute cough by motivating GPs to change their attitudes to communication and empowering patients: a cluster-randomized intervention study. J Antimicrob Chemother. 2007;60:638–44.
- [27] Gjelstad S, Hoye S, Straand J, Brekke M, Dalen I, Lindbaek M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study). BMJ. 2013;347:f4403.
- [28] Hürlimann D, Limacher A, Schabel M, et al. Improvement of antibiotic prescription in outpatient care: a cluster-randomized intervention study using a sentinel surveillance network of physicians. J Antimicrob Chemother. 2015;70:602–8.
- [29] ang L, Liu C, Wang L, et al. Public reporting improves antibiotic prescribing for upper respiratory tract infections in primary care: a matched-pair cluster-randomized trial in China.. Health Res Policy Syst. 2014;12:61.
- [30] Chen Y, Yang K, Jing T, et al. Use of text messages to communicate clinical recommendations to health workers in rural China: a cluster-randomized trial. Bull World Health Organ. 2014;92:474–81.
- [31] Gulliford MC, van Staa T, Dregan A, et al. Electronic health records for intervention research: a cluster randomized trial to reduce antibiotic prescribing in primary care (eCRT study). Ann Fam Med. 2014;12:344–51.
- [32] Van der Velden AW, Kuyvenhoven MM, Verheij TJ. Improving antibiotic prescribing quality by an intervention embedded in the primary care practice accreditation: the ARTI4 randomized trial. J Antimicrob Chemother. 2016;71:257–63.
- [33] Qiu JA. Review of the significance of clinical application of antibiotics and pharmaceutical. Int Resp Med. 2016;14:105–6.
- [34] Vervloet M, Meulepas MA, Cals JW, Eimers M, van der Hoek LS, van Dijk L. Reducing antibiotic prescriptions for respiratory tract infections in family practice: results of a cluster randomized controlled trial evaluating a multifaceted peer-group-based intervention. NPJ Prim Care Respir Med. 2016;26:15083.
- [35] Ferrat E, Le Breton J, Guery E, et al. Effects 4.5 years after an interactive GP educational seminar on antibiotic therapy for respiratory tract infections: a randomized controlled trial. Fam Pract. 2016;33:192–9.
- [36] Lee MHM, Pan DST, Huang JH, et al. Results from a patient-based health education intervention in reducing antibiotic use for acute upper respiratory tract infections in the private sector primary care setting in Singapore. Antimicrob Agents Chemother. 2017;61:e02257–16.
- [37] Tang Y, Liu C, Zhang X. Performance associated effect variations of public reporting in promoting antibiotic prescribing practice: a cluster randomized-controlled trial in primary healPCare settings.. Prim Health Care Res Dev. 2017;18:482–91.
- [38] Wei X, Zhang Z, Walley JD, et al. Effect of a training and educational intervention for physicians and caregivers on antibiotic prescribing for upper respiratory tract infections in children at primary care facilities in rural China: a cluster-randomised controlled trial. Lancet Glob Health. 2017;5:e1258–67.
- [39] Dekker ARJ, Verheij TJM, Broekhuizen BDL, et al. Effectiveness of general practitioner online training and an information booklet for parents on antibiotic prescribing for children with respiratory tract infection

in primary care: a cluster randomized controlled trial. J Antimicrob Chemother. 2018;73:1416–22.

- [40] Gulliford MC, Prevost AT, Charlton J, et al. Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster randomised trial. BMJ. 2019;12:364.
- [41] Du Yan L, Park D, Thompson J, et al. Education vs clinician feedback on antibiotic prescriptions for acute respiratory infections in telemedicine: a randomized controlled trial. J Gen Intern Med. 2021;36:305–12.
- [42] Mann D, McGinn T, Richardson S, et al. Impact of clinical decision support on antibiotic prescribing for acute respiratory infections: a cluster randomized implementation trial. J Gen Intern Med. 2020;35:788–95.
- [43] Boere TM, Hopstaken RM, van Tulder MW, et al. Effect of C reactive protein point-of-care testing on antibiotic prescribing for lower

respiratory tract infections in nursing home residents: cluster randomised controlled trial. BMJ. 2021;21:2198–021.

- [44] Zahlanie Y, Lin K, Hynan LS, et al. Improved antibiotic prescribing practices for respiratory infections through use of computerized order sets and educational sessions in pediatric clinics. Open Forum Infect Dis. 2020;8:601.
- [45] SPIRIT. The SPIRIT Statement Recommended items to address in a clinical trial protocol and related documents. Available at: https://www. spirit-statement.org/spirit-statement/ (access date December 1, 2021).
- [46] Luo M, Wei SB, Huang L, et al. Systematic evaluation and meta-analysis of kangfu anti-inflammatory suppository combined with antibiotics in the treatment of pelvic inflammatory disease. Chin J Antibiot. 2019;44:519–26.
- [47] Tang YQ, Du X, Wang HT, et al. Meta analysis of the effect of comprehensive intervention on reducing the utilization rate of antibacterial drugs in inpatients. Chin Pharm. 2013;24:2275–9.